Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of Potential Therapeutic Agents for Type I Interferonopathy Using iPSC-Based Disease Modeling.

Journal of clinical immunology - 30 Sept 2025

Natsumoto Bunki, Shoda Hirofumi, Tsuji Motonori, Otsu Makoto, Taniguchi Hideki, Yamamoto Kazuhiko, Fujio Keishi

Abstract excerpt

PURPOSE: Type I interferonopathy encompasses disorders marked by systemic inflammation and neurological involvement, arising from genetic mutations that result in the upregulation of type I IFN signaling through various mechanisms. Currently, therapeutic options are limited, and no standard therapy exists. This study aims to develop a strategy for identifying new therapeutic targets for type I interferonopathy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dendritic Cells
Share to Gene Expression Profiling

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Induced Pluripotent Stem Cells

Share to Interferon Type I

Share to Mitochondria

Share to Mutation

Share to Reactive Oxygen Species

Share to Signal Transduction

Source

Open in PubMed Open full text

Identifiers

PMID: 41026253
DOI: 10.1007/s10875-025-01933-8
PMCID: PMC12484275

Genes

IFIH1
PML
OASL

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of Potential Therapeutic Agents for Type I Interferonopathy Using iPSC-Based Disease Modeling.PMID 41026253Read ↗

Emergence of a stage-dependent human liver disease signature with directed differentiation of alpha-1 antitrypsin-deficient iPS cells.Semantic proximity Read ↗

ZBTB7B couples interferon response to mitophagy impairment and inflammasome activation in septic ARDSSemantic proximity Read ↗

iPSC-Derived Myogenic Progenitor Cells from People with ME/CFS Reveal Altered Genes and Pathways with Drug Repurposing PotentialSemantic proximity Read ↗

iPSC-Derived Myogenic Progenitor Cells from People with ME/CFS Reveal Altered Genes and Pathways with Drug Repurposing PotentialSemantic proximity Read ↗

The iPSC proteomic compendiumSemantic proximity Read ↗

Successful Correction of ALD Patient-derived iPSCs Using CRISPR/Cas9Semantic proximity Read ↗

ISG15 deficiency features a complex cellular phenotype that responds to treatment with itaconate and derivatives.Semantic proximity Read ↗

Mechanisms of IRF2BPL-related disorders and identification of a potential therapeutic strategySemantic proximity Read ↗

IFN-α Induces Heterogenous ROS Production in Human β-CellsSemantic proximity Read ↗

Comparison of human isogeneic Wharton’s jelly MSCs and iPSC-derived MSCs reveals differentiation-dependent metabolic responses to IFNG stimulationSemantic proximity Read ↗

Human iPSC-Derived Neural Stem Cells with ALDH5A1 Mutation as a Model of Succinic Semialdehyde Dehydrogenase DeficiencySemantic proximity Read ↗

Pseudohypoxia-stabilized HIF2⍺ transcriptionally inhibits MNRR1, a druggable target in MELASSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.